Clinical trials: Multiple Sclerosis, Chronic Progressive
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses…
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis
- Trial name
- NCT05029609
- Testing
- Intranasal Foralumab Solution
- Sponsor
- Tiziana Life Sciences LTD
Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive
Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Scientific background: Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade.
- Trial name
- NCT00220493
- Testing
- Ritalin
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Sheba Medical Center
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Motor Asymmetry in Progressive Multiple Sclerosis Patients
Project Rational A better understanding of the causes of physical disability is an important unmet need in progressive Multiple Sclerosis patients.
- Trial name
- MAP-MS (NCT04918225)
- Testing
- Magnetic Resonance Imaging, Neurological examination, Multiple Sclerosis Functional Composite
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Multiple Sclerosis
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
This was a retrospective cohort study using the electronic medical record (EMR) database from Cleveland Clinic. The data was analyzed at start of ofatumumab (OMB) therapy (baseline, defined as 6 months prior to OMB initiation)…
- Trial name
- NCT06737419
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Pathologic Processes
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
- Conditions
- Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases
- Trial name
- NCT03562975
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of South Florida
Secondary Progressive Multiple Sclerosis
AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
Patients with marked bladder dysfunction as a result of secondary progressive multiple sclerosis are being recruited to receive AIMSPRO or placebo by subcutaneous injection, in this double-blind crossover study.
- Trial name
- NCT01228396
- Testing
- Hyperimmune caprine serum against HIV lysate
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Daval International Limited
Multiple Sclerosis
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.
REPAIR-MS is a single-center open label, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed…
- Trial name
- REPAIR-MS (NCT03993171)
- Testing
- gold nanocrystals
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Clene Nanomedicine
Multiple Sclerosis (MS) Primary Progressive
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Trial name
- NCT07067463
- Testing
- Orelabrutinib
- Where
- 76 sites in United States, Bulgaria and 14 more
- Volunteers
- 705 people
- Sponsor
- Zenas BioPharma (USA), LLC
Multiple Sclerosis (MS)
Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis
The purpose of this study is to evaluate the clinical efficacy and the optimal way of administration of autologous mesenchymal bone marrow stem cells (MSC) compering intravenous injection and intrathecal injection vs.
- Trial name
- NCT02166021
- Testing
- Mesenchymal stem cells
- Where
- Israel
- Volunteers
- 48 people
- Sponsor
- Dimitrios Karussis
Progressive Multiple Sclerosis
Multiple Sclerosis Prediction and Monitoring of Progression Study
Multiple sclerosis (MS) is a auto-immune disease that is mostly characterized by acute clinical relapses and/or focal inflammation in the central nervous system (CNS) followed by recovery.
- Trial name
- PREMONITION (NCT05685784)
- Testing
- Bytelfies kit - sensor dot
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Functional Outcomes From Diets in Multiple Sclerosis
The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS).
- Trial name
- FOOD_for_MS (NCT05327322)
- Testing
- Glycemic load, Calorie restriction, Behavioral support
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Multiple Sclerosis
Armergometry to Improve Mobility in MS
Chronic progressive multiple sclerosis patients will be randomised to home-based arm ergometry training for 12 weeks or a waitlist control group which will have access to the treatment after 12 weeks when primary endpoint…
- Trial name
- AMBOS (NCT03147105)
- Testing
- arm ergometry
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06526364
- Testing
- All participants will be asked to provide data and samples for collection and analysis.
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Basel, Switzerland
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Treatment in Progressive Multiple Sclerosis
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
- Trial name
- NCT05349474
- Testing
- Metformin 500 Mg Oral Tablet, up to 4 tablets a day
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis, Primary Progressive
Aerobic Exercises for Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) .It is the most common neurological disorders affecting young adults.Multiple sclerosis is an autoimmune disease that…
- Trial name
- NCT04545372
- Testing
- aerobic exercise
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- South Valley University
Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting
Intermittent Hypoxia in Persons With Multiple Sclerosis
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06276634
- Testing
- Acute Intermittent Hypoxia
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Shirley Ryan AbilityLab
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
This was a multicenter, non-interventional, retrospective study aiming to evaluate the real-world effectiveness and safety of siponimod treatment in Chinese patients with relapsing forms of multiple sclerosis (RMS).
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06395909
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Novartis
Multiple Sclerosis
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
Phase IV open label, single-blind study, post-marketing, 1-year MRI observational study evaluating effect of Avonex® monotherapy (6.0 MIU administered i.m.
- Trial name
- NCT00463710
- Testing
- Avonex® monotherapy (6.0 MIU administered i.m. each week)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- State University of New York at Buffalo
Secondary Progressive Multiple Sclerosis
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
A present there is no safe treatment for reducing rate at which disability worsens in people with secondary progressive multiple sclerosis.
- Trial name
- NCT00257855
- Testing
- Lamotrigine
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- University College London Hospitals
Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
- Conditions
- Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Progressive Multiple Sclerosis (PMS), Relapsed/Refractory Myasthenia Gravis(r/r MS)
- Trial name
- NCT07583030
- Testing
- LVIVO-TaVec400 product
- Where
- 4 sites in China
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology